ProCE Banner Activity

New Data on Monoclonal Antibodies for Prevention and Treatment of COVID-19

Clinical Thought
Neutralizing antibodies are an attractive strategy for prevention and treatment of COVID-19, particularly for unvaccinated persons and others at high risk of infection. Here’s my take on 2 exciting new studies in this field.

Released: July 07, 2021

Expiration: July 06, 2022

Share

Faculty

Sharon R. Lewin

Sharon R. Lewin, AO, FRACP, PhD, FAHMS

Director, The Peter Doherty Institute for Infection and Immunity
Melbourne Laureate Professor and Head, Department of Infectious Disease, The University of Melbourne
Consultant Physician, Royal Melbourne and Alfred Hospitals
Melbourne, Australia

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Gilead Sciences, Inc.

Faculty Disclosure

Primary Author

Sharon R. Lewin, AO, FRACP, PhD, FAHMS

Director, The Peter Doherty Institute for Infection and Immunity
Melbourne Laureate Professor and Head, Department of Infectious Disease, The University of Melbourne
Consultant Physician, Royal Melbourne and Alfred Hospitals
Melbourne, Australia

Sharon Lewin, AO, FRACP, PhD, FAAHMS, has disclosed that she has received consulting fees from AbbVie, Gilead Sciences, and ViiV Healthcare; funds for research support from Leidos; and other financial or material support from Gilead Sciences, Merck, and ViiV Healthcare.